SVRA
Savara, Inc.
$4.22
-7.05%
2026-10-23
About Savara, Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
Key Fundamentals
Forward P/E
-16.03
EPS (TTM)
$-0.58
ROE
-105.5%
Profit Margin
0.0%
Debt/Equity
21.17
Price/Book
8.85
Beta
0.25
Market Cap
$1.02B
Avg Volume (10D)
1.7M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$5.99
60D Low
$4.13
Avg Volume
1.9M
Latest Close
$4.22
Get breakout alerts for SVRA
Sign up for Breakout Scanner to receive daily notifications when SVRA triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Savara, Inc. (SVRA) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors SVRA daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. SVRA operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.